Treatment for Vestibular Schwannoma (Acoustic Neuroma)
For small, asymptomatic vestibular schwannomas, observation with serial imaging is appropriate, while stereotactic radiosurgery (SRS) should be chosen over microsurgery when preserving facial nerve and hearing function is the primary goal; for large tumors causing mass effect, surgical decompression is mandatory. 1
Treatment Algorithm Based on Tumor Size and Symptoms
Small Tumors (Intracanalicular or <2cm)
Observation ("watch and scan") is considered appropriate for incidental, asymptomatic vestibular schwannomas. 1 Without intervention, 29-54% of tumors will grow and 16-26% of patients require additional treatment, with 54-63% preserving functional hearing. 2
As an alternative to observation, SRS can be performed upfront for small tumors. 1 The 2024 ISRS guidelines specifically address intracanalicular VS, noting that upfront treatment should provide equivalent or better results compared to conservative surveillance to be justified. 3 Recent evidence demonstrates that SRS for Koos grade I VS achieves 100% tumor control at both 5 and 8 years, compared to only 48.6% and 29.5% with observation at the same intervals. 4
For smaller VS where preserving facial nerve and hearing function is the primary goal of treatment, SRS over microsurgery should be chosen. 1 With radiosurgery, only 2-4% require additional treatment and hearing preservation is accomplished in 44-66% of cases. 2 A 2022 meta-analysis found that gamma knife radiosurgery (GKRS) stabilized hearing in 64% of patients and actually increased hearing capability in 10%. 5
Large Tumors (>2-3cm or Causing Mass Effect)
In large VS, surgery is considered the primary treatment to reduce mass effect. 1 Surgical decompression is mandatory when there is significant brainstem compression or symptomatic mass effect. 1
For large VS, tumor mass reduction followed by SRS or observation is a valid option. 1 This combined approach shows superior outcomes regarding facial nerve function and hearing preservation compared with total resection, with comparable tumor control rates. 1
Surgical Considerations
Extent of Resection
The goal of surgery should be total or near-total resection, since residual tumor volume correlates with rate of recurrence. 1 Recurrence rates are 3.8% for gross total resection (GTR), 9.4% for near-total resection (NTR), and 27.6% for subtotal resection (STR). 1 Patients with STR experience recurrences over 13 times more often than those treated with NTR. 1
However, for large VS, the lower risk of recurrence after GTR must be weighed against the higher risk for facial nerve dysfunction and lower rates of hearing preservation. 1 Partial resection followed by SRS has become increasingly popular for large tumors, showing superior facial nerve function and hearing preservation compared with total resection, with comparable tumor control rates. 1
Surgical Approaches
The choice of surgical approach depends on tumor characteristics and surgeon's expertise:
Suboccipital retrosigmoid (retromastoid) approach: Favored by neurosurgeons for tumors in the cerebellopontine cistern or with significant mass effect. Allows removal of various sizes with possibility of hearing preservation. 1
Translabyrinthine approach: Can remove tumors of all sizes but results in complete loss of inner ear function—not suitable for hearing preservation. Provides excellent facial nerve visualization. 1
Middle fossa approach: For small tumors (<1cm) when hearing preservation is desired. Requires careful patient selection. 1
Intraoperative Monitoring
Intraoperative neurophysiological monitoring is mandatory for VS surgery. 1 This should include:
- Somatosensory evoked potentials
- Facial nerve monitoring with direct electrical stimulation and free-running electromyography 1
- Brainstem auditory evoked responses when hearing preservation is attempted 1
- Electromyography of lower cranial nerves for large lesions 1
Radiosurgery Specifications
Stereotactic radiosurgery uses doses from 11 to 14 Gy in a single fraction for small to medium sized VS. 1 This can be performed using Gamma Knife (cobalt-60 based) or linear accelerator techniques like CyberKnife. 1 For larger tumors, fractionated radiotherapy or hypofractionated stereotactic radiotherapy (SRT) using up to 10 fractions is increasingly used. 1
SRS achieves tumor control in 96-98% of cases with only 2-4% requiring additional treatment. 2 Importantly, SRS was associated with reduced likelihood of tinnitus (OR = 0.46), vestibular dysfunction (OR = 0.17), and overall cranial nerve dysfunction (OR = 0.49) compared to observation. 4
Management of Recurrence
After intentional NTR or STR, a watch and scan policy is warranted as only a minority of remnants progress; however, the risk increases with the size of the remnant. 1
In VS recurring after surgery, radiosurgery should be used preferentially because the risk of damage to the facial nerve is lower than with a second operation. 1 The functional risk for the facial nerve upon surgery is higher after previous irradiation, requiring very meticulous, conservative dissection technique. 1
Pharmacotherapy
Except for bevacizumab in neurofibromatosis type 2, there is no role for pharmacotherapy in sporadic vestibular schwannomas. 1
Critical Pitfalls to Avoid
- Do not perform GTR on large tumors at the expense of facial nerve function—consider partial resection followed by SRS instead
- Do not use translabyrinthine approach if hearing preservation is desired—it results in complete loss of inner ear function
- Do not operate on recurrent VS after radiosurgery without careful consideration—facial nerve risk is substantially higher; radiosurgery retreatment may be preferable
- Do not skip intraoperative monitoring—it leads to improved functional outcomes and is considered mandatory